ReviewInternational journal of hematology2012
Combination strategies in myelodysplastic syndromes.
Review in International journal of hematology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 27 citations in OpenAlex.
- Azacitidine induced lung injury: report and contemporary discussion on diagnosis and management.Frontiers in oncology · 2024Review
- Novel spontaneous myelodysplastic syndrome mouse model.Animal models and experimental medicine · 2021Article
- Summary of animal models of myelodysplastic syndrome.Animal models and experimental medicine · 2021Review
- 5q- syndrome-like features as the first manifestation of myelodysplastic syndrome in a patient with an unbalanced whole-arm translocation der(5;19)(p10;q10).International journal of hematology · 2017Review
- Novel therapeutic strategies in myelodysplastic syndromes: do molecular genetics help?Current opinion in hematology · 2016Review
- inv(2)(p23q13)/RAN-binding protein 2 (RANBP2)-ALK fusion gene in myeloid leukemia that developed in an elderly woman.International journal of hematology · 2014Article
- Distribution of serum erythropoietin levels in lower risk myelodysplastic syndrome cases with anemia.International journal of hematology · 2014Article
- Long-term outcome of immunosuppressive therapy for Japanese patients with lower-risk myelodysplastic syndromes.International journal of hematology · 2013Article
- Decitabine: a review of its use in older patients with acute myeloid leukaemia.Drugs & aging · 2013Review
- Successful treatment by azacitidine therapy of intestinal Behçet's disease associated with myelodysplastic syndrome.International journal of hematology · 2013Article
- The need for additional genetic markers for myelodysplastic syndrome stratification: what does the future hold for prognostication?Expert review of hematology · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The myelodysplastic syndromes (MDS) consist of an array of clonal hematological malignancies resulting from disorders of pluripotent hematopoietic stem cells. MDS is associated with a poor overall prognosis and patients are categorized as higher risk and lower risk on the basis of the International Prognostic Scoring System. Currently, lenalidomide, azacitidine, and decitabine are the only three FDA-approved drugs for MDS. Traditional therapies for MDS involve the administration of single agents providing either supportive measures or disease-modifying effects directed to slowing progression to acute myeloid leukemia (AML) and improving survival. Recently, however, there has been increasing evidence suggesting that the combination of drugs with different mechanisms of action offers substantial benefit in the form of diminished side effects, improved overall survival, and delayed progression to AML. Multiple studies indicate that when compared with traditional monotherapies, combining various medications with non-overlapping mechanisms of action and toxicities may result in significant benefit for patients with MDS. A variety of combination therapies with growth factors, DNA methytransferase inhibitors, histone deacetylase inhibitors, and immunosuppressant treatments provide encouraging data indicating that the successful future of MDS treatment rests in the combination of multiple treatments modalities to achieve improved clinical outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.